Merz Therapeutics GmbH is a Frankfurt am Main-based pharmaceutical company focused on specialty neurology therapeutics. Launched in 2020 as a dedicated business unit within the family-owned Merz Group, it develops and commercializes treatments for movement disorders, spasticity, dystonia, Parkinson’s disease, and multiple sclerosis. Its flagship product is XEOMIN (incobotulinumtoxinA), a botulinum neurotoxin approved in numerous countries for therapeutic indications including cervical dystonia and blepharospasm. In 2024, Merz Therapeutics acquired INBRIJA (levodopa inhalation powder) and FAMPYRA (fampridine) from Acorda Therapeutics, expanding its portfolio in Parkinson’s disease and multiple sclerosis. The company operates in over 80 countries through partnerships, such as its collaboration with Teijin in Japan.
Official website: merztherapeutics.com
